newsfilter
← Latest News
GlobeNewswire·

Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update

  • Vivos Therapeutics reported a 24% quarter-over-quarter revenue increase to $6.4 million for the third quarter of 2026.
  • The company's operating loss improved 18% year-over-year to $3.9 million for the third quarter, driven by a 17% reduction in operating expenses.
  • Vivos regained compliance with Nasdaq's stockholders' equity requirement following a transaction closing in October 2026 & the exchange of $6.1 million in senior secured debt for equity.
  • General & administrative expenses declined by $1.4 million, while sales & marketing expenses dropped significantly, contributing to a total cost reduction of approximately $5 million annually.
  • Service revenue rose 1% to $4.6 million in the quarter, whereas product revenue fell to $1.8 million due to a strategic pivot away from appliance sales to dentists.
  • Net loss for the quarter was $2.0 million, which included $2.9 million in other income from the reversal of an Employee Retention Credit liability.
  • Cash & cash equivalents stood at $0.2 million at quarter end, with total stockholders' equity improving to $2.4 million from a deficit of $1.5 million the prior year.
  • Management expects new clinical initiatives, including EEG testing & payer contract renegotiations, to boost revenue & margins starting in the fourth quarter of 2026.
  • Operating expenses for the nine months ended September 30, 2026, increased to $24.7 million primarily due to costs associated with establishing two new Sleep & Airway Medicine Centers in Nevada.
  • A conference call to discuss these results & strategic initiatives is scheduled for 5:00 pm ET on November 16, 2026.
Company
Vivos Therapeutics, Inc
Keywords
Nasdaq:VVOS, Vivos Therapeutics, Inc